Alliqua to Launch Transdermal Patch Study
Alliqua, Inc., a wound management and drug delivery company, is launching a preclinical proof-of-principal study of an experimental hydrogel transdermal patch containing lidocaine.
In a release, James Saperstein, chief executive officer of Alliqua Biomedical, said that the lidocaine patch development program is just Alliqua's first step towards building a portfolio that leverages the company's hydrogel platform.
The lidocaine hydrogel patches will be developed with the intent to treat localized acute pain, including post-operative pain, back pain, and pain associated with sport injuries and arthritis.
Alliqua said results from this preclinical proof-of-principle study will be available later in the third quarter.
Alliqua results from a post-marketing study on their SilverSeal dressing displayed proof the dressing was shown to have a lower incidence of incision complications compared to standard petroleum- based dressing.
Alliqua is a biopharmaceutical company.
((Comments on this story may be sent to email@example.com))